= Emerging. More than 5 years before clinical availability. (19.79%)
= Expected to be clinically available in 1 to 4 years. (37.97%)
= Clinically available now. (42.25%)
MSACL 2022 : Badea

MSACL 2022 Abstract

Self-Classified Topic Area(s): Practical Training > Tox / TDM / Endocrine

Podium Presentation in Bonzai on Wednesday at 15:15 (Chair: TBA)

Oral Fluid as Alternative Matrix for Drug Testing: Clinical Utility and Method Development

Adina Badea, PhD, DABCC (1,2)
(1) Lifespan Academic Medical Center (2) The Warren Alpert Medical School of Brown University

Adina Badea (Presenter)
Lifespan Health/Rhode Island Hospital & The Warren Alpert Medical School of Brown University

Presenter Bio: Dr. Adina Badea, PhD, DABCC, earned her BA in Chemistry from Wellesley College, and her PhD in Chemistry from the University of Illinois at Urbana-Champaign. She completed her clinical chemistry and toxicology fellowship at UCSF, where she worked under the supervision of Dr. Alan Wu and Dr. Kara Lynch on developing methods and finding new solutions to current challenges in clinical toxicology testing. Currently, she is Director of Toxicology at Rhode Island Hospital and Assistant Professor of Pathology and Laboratory Medicine at The Warren Alpert Medical School of Brown University, where she focuses on expanding the capabilities of the clinical toxicology lab using high resolution mass spectrometry. Her research interests include bringing state-of-the-art testing to the service of emergency medicine patients and to address public health crises with real-time comprehensive toxicology testing via collaborations with the local Poison Control Center and Department of Health.

Abstract

Oral fluid is a promising alternative matrix for drug testing due to its non-invasive collection and minimal potential for adulteration. This session will provide an overview of oral fluid drug testing and oral fluid as a matrix for clinical testing. The feasibility of using oral fluid as a self-standing matrix for drug screens or in combination with blood or urine for confirmation will also be discussed, with examples of current practices and recent literature. Matrix specific factors to consider while developing an LC-MS/MS drug detection assay in oral fluid will then be discussed. Lastly, the session will present an overview of current method development efforts along with suggestions for getting started with an LC-MS/MS method for oral fluid drug testing based on lessons learned during the development and validation of a high-resolution mass spectrometry method for detecting a comprehensive pain management drug panel in oral fluid.

At the end of this session, attendees should be able to:

1. Understand the advantages and limitations of using oral fluid as a matrix for drug testing
2. Assess the clinical utility of oral fluid as a testing matrix for a specific application
3. Develop a plan for an LC-MS/MS assay in oral fluid to suit their drug detection needs.


Financial Disclosure

DescriptionY/NSource
Grantsno
Salaryno
Board Memberno
Stockno
Expensesno
IP Royaltyno

Planning to mention or discuss specific products or technology of the company(ies) listed above:

no